Andrew Weinberg

Company: AgonOx

Job title: Chief Executive Officer

Seminars:

Enhancing TIL Selection to Improve Specificity & Functionality 11:30 am

Enriching highly tumor-reactive CD8+ TILs by selecting CD39/ CD103 double-positive cells Expanding exhausted TILs into billions while retaining tumor killing functionality Demonstrating long-term persistence, trafficking, and efficacy in IL-2-supported clinical modelsRead more

day: Conference Day Two R&D Track AM